Performance analysis of Spyre Therapeutics (SYRE)
Annual Return
Over the past 3 years, SYRE has had an average annual return of +90.86%, outperforming the benchmark SPY, which returned +19.63% annual.
Over the past 5 years, SYRE has had an average annual return of -9.05%, underperforming the benchmark SPY, which returned +12.73% annual.
Over the past 10 years, SYRE has had an average annual return of -1.23%, underperforming the benchmark SPY, which returned +15.04% annual.
Since Apr 7, 2016, SYRE has had an average annual return of -8.07%, underperforming the benchmark SPY, which returned +15.31% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +213.57% | +40.71% | +8.17% | +91.52% | -90.54% | -39.64% | +3.01% | +2.01% | +38.45% | +24.37% | -55.48% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.39% | +34.53% | +17.26% | +47.60% | -1.28% | +20.80% | +15.68% | +213.57% | |||||
| 2025 | -1.26% | -14.24% | -18.09% | -5.60% | +0.32% | -2.08% | +13.38% | -2.88% | +1.63% | +45.92% | +22.68% | +9.20% | +40.71% |
| 2024 | +20.43% | +5.84% | +38.29% | -12.94% | +5.84% | -32.70% | +16.93% | +4.53% | +2.29% | +10.63% | -12.61% | -18.13% | +8.17% |
| 2023 | +11.30% | -21.68% | -25.94% | -41.75% | -23.12% | +246.62% | +25.38% | +1.90% | -14.77% | -4.98% | +60.17% | +15.31% | +91.52% |
| 2022 | -9.48% | -35.58% | -16.97% | -37.38% | +9.70% | -68.03% | -17.79% | +25.88% | +0.56% | +95.91% | -59.68% | +8.24% | -90.54% |
| 2021 | -11.68% | +7.18% | +6.31% | -1.76% | -15.03% | +5.29% | -11.93% | +18.28% | +9.65% | -7.93% | -14.75% | -23.88% | -39.64% |
| 2020 | -4.97% | -5.92% | -31.77% | +66.73% | +13.38% | +5% | -25.95% | +6.20% | -2.54% | +8.32% | +11.46% | -8.07% | +3.01% |
| 2019 | +22.03% | -8.53% | -3.70% | -14.92% | -8.90% | +9.77% | +30.81% | -12.89% | -1.48% | -1.04% | +12.35% | -10.64% | +2.01% |
| 2018 | +19.79% | +11.88% | +36.83% | -5.85% | +14.34% | -0.93% | -20.51% | +29.96% | -12.44% | -9.82% | -2.43% | -11.05% | +38.45% |
| 2017 | -8.27% | +55.39% | +20.15% | -4.03% | -40.98% | -8.75% | -11.44% | +20.54% | +19.94% | -11.16% | -8.68% | +35.25% | +24.37% |
Drawdown analysis of Spyre Therapeutics (SYRE)
The maximum drawdown for the SYRE was -99.11%, occurring on Jun 21, 2023. This drawdown has not yet recovered.
The current SYRE drawdown is -65.74%.
Since Apr 7, 2016 SYRE has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.11% | Apr 8, 2016 | 1812 | Jun 21, 2023 | Ongoing | Ongoing | Ongoing |